Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Fast Company David Lumb	The FDA Just OK'd 23AndMe To Test For One Syndrome The FDA just gave consumer genetics testing company 23AndMe permission to sell tests for Bloom syndrome -- a disease associated with shortened height and an increased cancer risk.
Chemistry World February 25, 2015 Rebecca Trager	US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests.
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
AskMen.com Jacob Franek	Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs?
Fast Company November 2013 Elizabeth Murphy	To Know You Is To Really Know You A deeper look at the makeup of genetic testing firm 23andme's customers and what their DNA reveals.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
Wired November 17, 2007 Thomas Goetz	23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons.
Fast Company November 2013 Elizabeth Murphy	Inside 23andMe founder Anne Wojcicki's $99 DNA Revolution If Wojcicki gets it right, 23andMe could help change the health care industry as we know it. "At $99, we are opening the doors of access," she says. "Genetics is part of an entire path for how you're going to live a healthier life."
Pharmaceutical Executive September 1, 2010	The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.
Chemistry World March 23, 2015 Andrew Turley	23andMe jumps into drug R&D 23andMe plans to create a therapeutics group that will search for new leads using its database as a research platform.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Fast Company John Paul Titlow	23andMe Wants To Turn Your DNA Data Into Lucrative New Drugs 23andMe's original business model may have been thwarted by the feds, but that isn't stopping the company from trying new ways to generate revenue. Its latest idea could be a lucrative one: invent new drugs.
Managed Care May 2001 Michael D. Dalzell	Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use...
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
Fast Company Pavithra Mohan	App Used 23andMe's DNA Database To Block People From Sites Based On Race And Gender Personal genetics company 23andMe discovered that a programmer had used its open API to create a screening mechanism for websites -- which could effectively block people by race, sex, and ancestry.
The Motley Fool November 30, 2010 Brian Orelli	Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.
The Motley Fool September 24, 2007 Jack Uldrich	Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note.
Fast Company December 1, 2007 Amanda Bower	Are There Holes In My Genes? A new industry promises to gauge your genetic risk of getting diseases like cancer. Its investors, including John Doerr's Kleiner Perkins and Mark Kvamme's Sequoia Capital, have bet millions that consumers will buy it. Here, the author takes a test.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Managed Care June 2004 Thomas Morrow	Laronidase Opens Door To Treat Other Rare Disorders The release of alpha-L-iduronidase also demonstrates the wave of future treatments for many other mucopolysaccharidosis (MPS) diseases.
BusinessWeek January 21, 2010 Rich Jaroslovsky	Web DNA Tests Offer Ease and Enlightenment A comparison of the often entertaining services of Navigenics, 23andMe, and deCODEme.
Scientific American June 2009 Melinda Wenner	Genetic Copy Variations and Disease A new sense for how variable numbers of genes cause disease.
HHMI Bulletin May 2012 Sarah C. P. Williams	Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies.
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
BusinessWeek October 23, 2008 John Carey	Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon.
Managed Care August 2004 Thomas Morrow	10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans.
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
Chemistry World June 6, 2007 Simon Hadlington	Large-Scale Gene Scanning for Common Diseases A multi-center genome scanning project that has analyzed half a million genetic markers in thousands of healthy people and people with a range of common diseases has revealed previously unknown genetic variants of the diseases.
Wired November 17, 2007 Thomas Goetz	What My Genome Says About Me The gene variations that lead to the most popular diseases in the U.S.
AskMen.com August 19, 2001 Joshua Levine	The Ins & Outs Of Heredity If you've ever worried that you might inherit something undesirable from your parents, this is your article...
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
BusinessWeek June 13, 2005 John Carey	The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications.
Fast Company David Lumb	Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period.
BusinessWeek May 9, 2005 John Carey	Dr. Francis S. Collins: On The Trail Of Disease Genes Collins is leading the search for DNA variations that can result in illnesses.
The Motley Fool August 27, 2007 Brian Lawler	Round 2 for Genentech Learn a lesson or two from Genentech's's dance with the FDA. The drugmaker's experience serves as a reminder of the fickle nature of the government agency, and the sometimes frustrating process of bringing a medication to market.
Managed Care September 2002	Aetna Chief Wants Coverage For Genetic Tests The CEO of the country's largest for-profit HMO has jumped with both feet into the national discussion about genetic testing's place in health care.
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
BusinessWeek May 9, 2005	A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool August 17, 2007 Brian Orelli	FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool February 25, 2011 Brian Orelli	When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections?
BusinessWeek November 7, 2005 Catherine Arnst	How Likely Are You To Get Sick? A new DNA database could gauge your risk for disease.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 16, 2008 Brian Orelli	Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know.